1 Apparent species differences in the responses of recombinant P2X(7) recep
tors to repeated application of 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP)
have been investigated.
2 Repeated application of 100 mu M BzATP resulted in a progressive increase
in current magnitude (current growth) at mouse and human, but not rat P2X(
7) receptors.
3 Current growth was thought to reflect progressive dilation of the P2X(7)
ion-channel to a pore permeable to large molecules (MW < 900), suggesting t
hat channel dilation was not occurring at the rat P2X(7) receptor. However,
100 mu M BzATP produced a rapid influx of YO-PRO-1 (MW375) in cells expres
sing rat or human P2X(7) receptors.
4 There were, however, species differences in agonist potency such that 100
mu M BzATP was a supra-maximal concentration at rat, but not human or mous
e, P2X(7) receptors. Importantly, when sub-maximal concentrations of BzATP
or ATP were examined, current growth occurred at rat P2X(7) receptors.
5 The rate of current growth and YO-PRO-1 accumulation increased with agoni
st concentration and appeared more rapid at rat and human, than at mouse P2
X(7) receptors.
6 The potency of BzATP and ATP was 1.5-10 fold lower in naive cells than in
cells repeatedly exposed to ATP.
7 This study demonstrates that current growth occurs at mouse, rat and huma
n P2X(7) receptors but only when using sub-maximal concentrations of agonis
t. Previously, current growth was thought to reflect the progressive increa
se in pore diameter of the P2X(7) receptor ion channel, however, the result
s of this study suggest a progressive increase in agonist potency may also
contribute.